CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1.

"Conflict of interest Authors LS, Y-LC, C-CH, D-SC, and Y-WC were employed by the company TaiRx, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare Inoviem Scientific performed the target identification using their own proprietary technology NPOT, and provided valuable discussion on the evaluation and confirmation of the identified target."

"The authors declare that this study received funding from TaiRx, Inc.. Five employees of this company were involved in the study design, collection, analysis, interpretation of data, and the writing of this article, in collaboration with several scientists from other institutions, but the funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to publish."